Search

Displaying results 4621 - 4630 of 10000 in total
  1. Drug

    Diloxanide furoate

    go.drugbank.com/drugs/DB14638
    ApprovedInvestigational

    Synonyms: 2,2-dichloroacetamido-4-n-methylphenyl 2-furoate, 4-(n-methyl-2,2-dichloroacetamido)phenyl 2-furoate
  2. Drug

    Cefaclor

    go.drugbank.com/drugs/DB00833
    ApprovedInvestigational

    Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.

  3. Drug

    Fluasterone

    go.drugbank.com/drugs/DB06250
    Experimental

    Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

  4. Drug

    Procaterol

    go.drugbank.com/drugs/DB01366
    ApprovedWithdrawn

    It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

  5. Drug

    Amobarbital

    go.drugbank.com/drugs/DB01351
    ApprovedIllicit

    Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)

  6. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.

  7. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  8. Drug

    Pirlindole

    go.drugbank.com/drugs/DB09244
    Experimental

    Pirlindole is a selective, reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in several European and non-European countries for the treatment of major depression. … This drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia.

  9. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

  10. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)). … POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).